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1. Introduction 
The aim of this chapter is to achieve a synthesis of the major studies existing in the literature 
on correlations between lipid metabolism and malignant hemopathies. We will expose the 
fundamental research data and their impact on clinical treatment. The purpose of this 
review is to help the clinicians to understand better the pathological disorders of the lipid 
metabolism and use the existing therapeutic arsenal to improve the treatment outcomes. The 
research and the recognition of the presence of dyslipidemia is useful, as well as monitoring 
them during oncological therapy. The treatment of dyslipidemia may not be only an option 
when a patient with malignant hemopathy has acquired multidrug resistance. It can 
contribute to reversing this resistance, but it can also have adverse effects that must be 
recognized, followed and treated. 
There are numerous studies in literature, but the connection between blood levels of various 
lipid fractions and hematologic malignancies is still unknown (Cvetkovic et al., 2009). 
Various epidemiological studies have found that between blood lipids and various 
neoplastic diseases there are correlations, thus the question is whether in the pathogenesis of 
cancer are not involved various lipid disorders (Moschovi M et al., 2004). At the same time it 
is believed that in patients with metabolic syndrome (MS), blood lipid levels may have 
correlations with the risk of cancer (Ulmer H et al., 2009). 
2. The lipid profile evolution under cancer treatment 
Cvetkovic & al. studied 47 patients with malignant non-Hodgkin's lymphoma (NHL) and 
found that before the treatment, compared with patients in the control group, blood levels of 
phospholipids, cholesterol (CH) and high density lipoprotein-cholesterol (HDL-cholesterol) 
had significantly lower values. After chemotherapy (3 or 6 cycles) the blood lipid levels 
reached even lower values in patients where the disease progressed, as opposed to those 
who achieved complete remission or whose disease was stationary, cases in which lipids 
increased progressively. (Cvetkovic et al., 2009). 
In an other study conducted in Poland on the lipid levels of 238 patients with different 
hematological malignant diseases Kuliszkiewicz-Janus M et al. found that HDL-cholesterol 
values were significantly different from those of patients in the control group when the 
disease was in active phase, but in the remission phase the difference was statistically 
significant only in patients with NHL and acute leukemia (Kuliszkiewicz-Janus et al., 2008).  
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In a health investigation conducted on 156,153 subjects, with 5079 incident cancers in men 
and 4738 cancers in women, and a mean of 10.6 years of survey, there was an inverse 
association between serum triglyceride (TG) levels and NHL (2). But in the study conducted 
by Kuliszkiewicz-Janus M et al., the TG value increased in the active disease period in all the 
hematological malignancies besides NHL (Kuliszkiewicz-Janus et al., 2008). 
Mihăilă R and al. made a cross-sectional research on all the patients with chronic 
lymphocytic leukemia (CLL) existing in a county department of hematology and a group of 
volunteer subjects from the medical staff with no malignant pathology. They found an 
augmentation of TG values in the patients with CLL (p <0.00001), an argument for a 
possible link between the MS and chronic lymphoproliferations. Hypercholesterolemia 
present in the patients with CLL from the above study may have consequences regarding 
the multiple drug resistance, subject to further future study. (Mihăilă et al., 2010) 
Nearly all the children with ALL when diagnosed and during chemotherapy revealed a 
predictable model of serum dyslipidemia that consisted of very low levels of HDL-
cholesterol, and elevated TG, and low-density lipoprotein cholesterol (LDL-cholesterol), that 
regained normal values during the remission period (Moschovi et al., 2004). 
In patients with secondary hemophagocytic syndrome an augmentation of TG was observed 
when diagnosed or during the disease period and TG values decreased when the disease 
improved under treatment (Okamoto et al., 2009). In patients with aggressive T cell 
lymphoma, fasting TG level was higher in those with hemophagocytic syndrome group 
than in the patients who had no hemophagocytic syndrome (Tong et al., 2008). 
3. The consequences of treatments with antineoplastic drugs 
In children with acute lymphoblastic leukemia (ALL), treated with asparaginase 
dyslipidemia was frequently observed (Cohen et al., 2010). 
A child heterozygote for apolipoprotein E 3/4 and with ALL who received pegasparaginase, 
presented an important aumentation of serum TG value, which normalized after continuous 
insulin infusion (Lawson et al., 2011). Another patient with a heterozygote type of familial 
lipoprotein lipase defect syndrome developed an important increase of serum TG value that 
was treated by three plasma exchanges with frozen plasma (Nakagawa et al., 2008).  
An adult patient with ALL also had an acute pancreatitis because of an important 
hypertriglyceridemia that appeared after asparaginase administration (Kfoury-Baz et al., 
2008), as well as a 10 years old boy who had been previously treated with asparaginase and 
corticosteroids (Ridola et al., 2008), both successfully treated by plasmapheresis sessions 
(Kfoury-Baz et al., 2008; Ridola et al., 2008).  
In a group of children and adolescent patients recently diagnosed with ALL during 
treatment a progresive increase of serum CH values to 274+/-124 mg/dl was observed. In 
this group of patients the average value of TG during tratment was 459+/-526 mg/dl. Two 
patients had hypertriglyceridemia-related complications: a thrombosis of saggital sinus and 
an infarct of the left frontal lobe. The observed dyslipidemia disappeared in all children after 
the asparaginase administration (Cohen et al., 2010).  
A prospective study assessed the lipid levels in children with ALL. At diagnosis, there was a 
significantly low level of total CH and HDL-cholesterol and at the same time a high level of 
TG. The patients were treated with the ALLIC 2002 protocol (including L-asparaginase), 
during which the values of total CH and HDL-cholesterol augmented, but they still 
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remained lower than for the control group. The main serum TG level was significantly 
higher as compared to that of witnesses (Zalewska-Szewczyk et al., 2008).  
A retrospective analysis showed that imatinib mesylate, used for the treatment of patients 
with chronic myeloid leukemia, led to a diminishing of serum CH and TG values 
(Franceschino et al., 2008). In a Romanian patient with chronic myeloid leukemia who 
received usual-dose of imatinib mesylate, a rapid and sustained normalization of serum CH, 
TG, low- and high-density lipoproteins and glucose values was found (Gologan et al., 2009).  
In some types of leukemia it was found that Kit receptor tyrosine kinase is overexpressed in 
a pathological manner, also that CH depletion was able to prevent Kit-mediated activation 
of the phosphatidylinositol 3-kinase downstream target Akt, which inhibits cell proliferation 
(Jahn et al., 2007).  
The treatment of cutaneous lymphomas with T cells using bexarotene can produce a serum 
TG augmentation, as in the three cases reported. The treatment with fenofibrate is 
recommended, but if adverse effects occure or a statin is needed to reduce 
hypertriglyceridemia, omega-3 fatty acids may be a therapeutic solution during the 
bexarotene administration. (Musolino et al., 2009) 
4. Is the metabolic syndrome a risk factor for some malignant hemopathies? 
The main risk factors for excess weight and obesity are high caloric diet and sedentary 
lifestyle. A study conducted in a county hospital in Transylvania examined the presence of 
MS in all 56 patients with NHL existing in its records and a control group of 64 consecutive 
patients with non-cancerous diseases in the same hospital (control group). Patients with 
NHL had significantly more frequently arterial hypertension, significantly higher body 
mass index values, and a significantly higher number of components of the MS as compared 
to those of the control group. This observation advocates the idea that excess weight may be 
a risk factor for this type of neoplasia. (Mihăilă et al., 2009) 
In a group of 170 non-Hispanic white pediatric cancer survivors, among males, body 
adiposity was more important in survivors than in witnesses, as was trunk fat. The 
survivors had higher values of CH, TG, LDL-cholesterol than the witnesses, and the first 
watched TV more hours than controls (Miller TL et al., 2010). It was observed that the young 
survivors of ALL, disease which they had in their childhood, especially those who received 
cranial radiotherapy, are likely to develop hyperlipidemia, insulin resistance, obesity, 
arterial hypertension and even MS soon after the treatment (Trimis et al., 2007).  
After an average period of 37 months after the end of type ALL-BFM 90 chemotherapy 
protocol, out of 52 patients almost half were overweight, nearly 6% - obese, more than half 
had at least one risk factor for MS, and about 6% had MS (Kourti et al., 2005).  
It was found that the consequences of treatment performed for ALL during childhood may 
become manifest when subjects reach adulthood. Cranial irradiation favors more the 
appearance of MS: 60% of those who had been so treated had at least two of the five 
components of MS when they become adults, and only 20% of those who had not been 
irradiated. The pathogenetic mechanism that explains the metabolic effects of cranial 
irradiation implies growth hormone (GH) deficiency, lower level of insulin-like growth factor 
1, fasting hyperinsulinemia, abdominal obesity and hyperlipidemia, especially in women 
(Gurney et al., 2006). In another study, ALL survivors who received cranial irradiation 
developed more frequently MS than those nonirradiated (23% towards 7%), probably because 
of higher prevalence of excess weight and arterial hypertension (van Waas et al., 2010).  
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In a study conducted on a group of 184 adults who had ALL in their childhood, the overall 
prevalence of MS has been even higher - 9.2%. Peripheral stem cell allografts after total body 
irradiation favored the occurrence of hypertriglyceridemia, low HDL-cholesterol and 
increased fasting glucose level (Oudin et al., 2011).  
In Sweden a group of adults was analysed; they survived after ALL during childhood and 
were submitted to radio-and chemotherapy. Those who received treatment for 5 years with 
GH compared with those not treated so for 8 years, showed significant changes in HDL-
cholesterol, glucose and apolipoprotein B / apolipoprotein A1 ratio, and MS was 
significantly less frequent. (Follin et al., 2010) 
Another study conducted in Sweden on adults who had childhood leukemia, found an 
augmentation of total body fat, especially of trunk adiposity and an evolution towards an 
unfavorable lipid spectrum. These observations were correlated with low levels of 
endocrine secretion of GH, a consequence of previous cranial irradiation. (Jarfelt et al., 2005) 
An interesting combination of diseases was described in a 54 years old woman: after being 
diagnosed with chronic neutrophilic leukemia a liver biopsy was made. The 
histopathological diagnosis was of nonalcoholic steatohepatitis (NASH) with neutrophilic 
infiltrate. The authors consider that the leukemia cells that infiltrated the liver contributed to 
the emergence of NASH. The administration of cytosine arabinoside contributed to a 
significant decrease in fat degeneration. (Yoshida et al., 2004)  
There are few studies on the metabolism of chylomicrons in patients with cancer. The study 
of a group of patients with Hodgkin and nonHodgkin lymphoma, as compared to a healthy 
control group, led to the observation that after an intravenous administration of a 
chylomicron-like emulsion, the levels of CH, TG and VLDL were significantly higher in 
patients with lymphoma because of the profound disturbance of the chylomicrons lipolysis 
and their removal deficit. (Gonçalves et al., 2003) 
A very interesting observation was achieved in a line of promyelocytic leukemia NB4 cells: 
the administration of peroxisome proliferator-activated receptor gamma ligands was able 
not only to induce differentiation but also to favor lipogenesis in NB4 cells. This fact 
suggests a close link between differentiation and lipogenesis process in human myeloid cells 
thus stimulated. (Yasugi et al., 2006). 
5. Cholesterol metabolism disorder  
It is known that cell membranes contain lipid rafts, belonging to CH-rich microdomains. 
These components of the cell membrane are involved in intracellular signal transduction 
processes mediated by the receptor and in the self-renewal of ES cells. (Lee et al., 2010) The 
administration of methyl-beta-cyclodextrin, that is a CH-sequestering agent useful for the 
lipid raft destruction, is able to restore the activity of large conductance background K(+) 
channels. This favors the activation by stretch. (Nam et al., 2007) The depletion of CH from 
the cell membranes leads to lipid rafts destruction, that are responsible for bloking the 
translocation of leukemia inhibitory factor receptor and gp 130 (Port et al., 2007).  
A group of Russian researchers studied the role of membrane CH in a line of human 
leukaemia K562 cells regarding the regulation of mechanosensitive cation channels activated 
by stretch. They consider that the above-mentioned suppression of this channel activation in 
leukemia cell line by methyl-beta-cyclodextrin is produced by F-actin rearrangement due to 
lipid raft destruction. (Morachevskaya et al., 2007) 
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In the regulation of lipid and CH metabolism liver X receptors are also involved, they are 
nuclear receptors. They can modulate the proliferation and survival of both normal and 
malignant B and T lymphocytes. (Geyeregger et al., 2009) 
The correlation between increasing CH in lipid domains and the possible cancerosus cell 
transformation is very interesting (Ajith et al., 2008). It is believed that CH is important for 
cell proliferation, because low serum CH values may be the result of high cellular CH need 
of cancerous cells. Low serum CH values correlate with elevated levels of CH in 
lymphocytes. Evidence of low levels of CH in the culture medium is due to the development 
of lymphoma cells, which would consume more CH for their own proliferation. The 
experimental administration of mevastatin in vitro, which inhibits CH synthesis, did not 
determine a significant variation of the concentration of CH in the culture medium, while 
cell growth diminished. (Pugliese et al., 2010) 
Low serum CH levels are also frequently found in acute leukemia patients. These patients 
have significantly lower serum values of CH, HDL-cholesterol, and LDL-cholesterol. A 
possible explanation for the low levels of HDL-cholesterol in the patients with acute 
leukemia could be an increased expression of a possible selective site for HDL-cholesteryl 
ester. (Gonçalves et al., 2005) 
Malignant, proliferative cells have an intense metabolism of CH, while decreased intake of 
CH is responsible for decreasing cell proliferation. In a human line of promyelocytic HL-60 
cells, an inhibition of cell cycle progression from G2 phase can be obtained by an enzymatic 
inhibition of CH synthesis at a stage before 7-dehydrocholesterol production. Drugs such as 
zaragozic acid or SKF 104976 can induce the expression of antigen 11c, a cluster of 
differentiation. These products have a comparable action to all-trans retinoic acid, which 
induces monocyte differentiation. (Sánchez-Martín et al., 2007) 
Chronic lymphocytic leukemia (CLL) is a heterogenous malignant hemopathy. In these 
patients, in the presence of UM-IGHV, which is a negative prognostic factor, there are 
increased levels of CH and lactate and low levels of glycerol and 3-hydroxybutyrate. 
(MacIntyre et al., 2010) 
CD5 antigen is responsible for CH synthesis and even for adipogenesis. It is known that 
malignant cells from CLL are undergoing a process of continuous stimulation due to CD5 
activation and cell survival. (Gary-Gouy et al., 2007) A continuous activation of an 
antiapoptotic pathway explains the CLL cells survival. Apolipoprotein E4-very low density 
lipoproteins is responsible for the high level of apoptosis in CLL cells. Lipoprotein lipase is 
the enzyme that metabolizes very low density lipoproteins to low-density lipoprotein. It was 
observed that an increase of lipoprotein lipase mRNA levels is present in CLL patients with 
shorter survival. (Weinberg et al., 2008) 
CH synthesis is also increased in patients with T-ALL who are glucocorticoid resistant 
(Beesley et al., 2009). 
The growth of a promyelocytic leukemia cell line – HL-60 can be experimentally supressed 
by sodium cholesteryl sulfate, cholesteryl bromide, and cholesteryl-5alpha. The first two are 
responsible for the cell arrest in S and G2/M phases, and the last product – in the G2/M 
phase. (Ishimaru et al., 2008) 
It was found that in xenotransplanted severely combined immunodeficient mice the most 
abundant bone marrow CH amounts are located in leukemia-rich sites. In vitro, in leukemic 
cells CH is able to stimulate FLT-1 expression and VEGF production. Human leukemic cells 
from patients with AML are significantly richer in CH than normal cells and this CH 
augmentation represents a marker of aggressive evolution. (Casalou et al., 2011) 
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6. Experimental and clinical observations on cholesterol metabolism disorder 
ABCA1 and ApoA-I are responsible for the efflux of CH in human monocyte leukemia cell 
line derived foam cells. This decrease of the concentration of CH can be enhanced by 
administration of rosiglitazone. (Lü et al., 2010) Animals fed on alternate days have showed 
lower incidence of lymphomas, after tumor inoculation have had higher survival, and some 
types of cells have proliferated more slowly. It seems that this diet in humans would favor 
increased levels of HDL-cholesterol and lower those of triacylglycerol. (Varady et al., 2007) 
It was found that ether phospholipid edelfosine is able to accumulate and selectively destroy 
mantle cell lymphoma and CLL cells, underlining the importance of the action on lipid rafts 
and Fas/CD95 for the therapy of these lymphoproliferations. CH depletion is involved in lipid 
raft disruption and in the diminishing of drug captation. (Mollinedo et al., 2010)  
Some clinical observations on the presence of dyslipidemia in patients with malignant 
hemopathies are presented in Table 1. 
 
Author Disease Dyslipidemia 
Inamoto et al., 2005 ALL + cholestasis from 
graft versus host disease 
hypercholesterolemia 
Lim et al., 2007 NHL serum HDL-cholesterol 
decrease 
Gokhale et al., 2007 NHL serum total CH level was 
significantly higher in 
patients who completed the 
treatment for NHL than in 
those who completed ALL 
therapy 
Garg et al., 2011 intravascular large B cell 
lymphoma 
low serum levels of HDL-
cholesterol 
Helman et al., 2011 MALT + obesity hypercholesterolemia 
MALT = mucosa-associated lymphoid tissue lymphoma  
Table 1. Examples of dyslipidemia in patients with malignant hemopathies. 
7. The cholesterol and the treatment with anti-CD20 monoclonal antibodies 
It has been noted that the loss of CH is responsible for the decrease in the number of sites 
that can fix some monoclonal antibodies, including CD20. CH depletion or Shiga-like toxin 
binding have been causes of disruption of CD20 localization, but not of CD77 in lipid rafts. 
(Jarvis et al., 2007) 
DXL625 is an anti-CD20 monoclonal antibody, capable of causing independently in vitro 
apoptosis of a lymphoma B cells line. This apoptosis is inhibited by the loss of membrane 
CH or of chelation of extracellular calcium, fact that underlines the role of lipid raft and 
calcium in this process. (Bingaman et al., 2010) 
Many lymphoproliferations with B cells have indication of treatment with rituximab, an 
anti-CD20 antibody. The inhibitor therapeutic effect of rituximab occurs at the same time as 
the decrease of CH deposits from lipid rafts, with decreased B-cell receptor relocation to 
lipid rafts structures, and with the disruption of the expression of BCR immunoglobulin, 
lowering it. (Kheirallah et al., 2010) 
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The first monoclonal antibody that was approved for the treatment of B-cell 
lymphoproliferative malignancies was rituxan, a chimeric monoclonal anti-CD20 antibody.  
It has been observed that the monoclonal antibody attachment to CD20 produces a 
redistribution of these antigens to lipid rafts, which are specialized membrane 
microdomains. If rituxan is not used, the CD20 antigen affinity to lipid rafts is small. 
Intracellular calcium entry and apoptosis have been completely eliminated experimentally 
by extracting CH, which has led to the destruction of the integrity of lipid raft structures and 
to the dissociation of CD20 antigen from a fraction that is resistant to Triton X-100. From this 
it results that for the activation of caspase induced by CD20- lipid rafts appear to have an 
essential role. (Janas et al., 2005) 
In multidrug resistance two populations of P-glycoprotein (P-gp) are involved. One is 
located in the membrane regions that are resistant to detergent; it has optimal P-gp ATPase 
activity; the verapamil can activate it and the orthovanadate can inhibit it almost entirely. 
The other population is located in another part of the membrane; it has less activity than P-
gp ATPase of the first population; the verapamil can inhibit it, and its sensitivity to the 
orthovanadate is less. The first population of Pgp is surrounded by deposits of CH that may 
have the role to stimulate the P-gp ATPase activity, but the CH near the second population 
of Pgp does not seem to have such a role. (Barakat et al., 2005) 
Rituximab induced apoptosis may be diminished by depletion of membrane deposits of CH, 
which does not allow the association to the detergent-insoluble lipid rafts of the antigen 
hypercrosslinked CD20. Under the action of rituximab, the antibody-bound CD20, found in 
lipid rafts in a high-affinity structure, activates src family kinases, interfering with the 
signal-transmission mechanism, which it inhibits. (Unruh et al., 2005) 
Besides their CH-lowering effects, statins have pleiotropic effects, including the 
antileukemic ones observed in vitro and in vivo (Sassano et al., 2009), but they disrupt the 
binding (Winiarska et al., 2008) and the antitumour activity of rituximab (Ennishi et al., 
2010), as a consequence of the changing of the antigen CD20 conformation (Ennishi et al., 
2010; Winiarska et al., 2008). Statins interfere with the detection of CD20 as well as the 
antilymphomatous function of the rituximab (Winiarska et al., 2008). But in a study that 
analyzed the progression-free survival in 3 years and overall survival in a group of patients 
with diffuse large B-cell lymphoma, including some patients who were taking statins, it was 
found that there were no statistically significant differences, fact that advocates the idea that 
statins used in clinical treatment do not alter the prognosis of patients with diffuse large B-
cell lymphoma under R-CHOP treatment. (Ennishi et al., 2010) 
8. Statins as adjuvant treatment in malignant hemopathies 
After chemotherapy, the blasts of acute myeloid leukemia (AML) respond by increasing 
cellular content of CH, which increases resistance to treatment. (Kornblau et al., 2007) Statins 
are pharmacologic inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA 
reductase) - the regulatory enzyme of CH synthesis (Nonaka et al., 2009; Sassano et al., 
2007). In vitro, they block HMG-CoA reductase and by this they contribute to restore 
sensitivity to chemotherapy. (Kornblau et al., 2007) HMG-CoA regulates not only the 
synthesis of CH but also that of the higher isoprenoids, as geranylgeranyl pyrophosphate 
(Fuchs et al., 2008). By the inhibition of the prenylation processes, in vitro, statins reduce 
cellular proliferation and stimulate apoptosis of cancerous cells (Nonaka et al., 2009; Sassano 
et al., 2007). It was found that simvastatin inhibits geranylgeranylation processes of small 
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GTPases Rab5B and Rac1 in certain leukemic cells (for example, adult T-cell leukemia). 
(Nonaka et al., 2009) 
The excessive proliferation inhibition induced by simvastatin results from the induction of 
apoptosis, cell cycle arrest in phase G2 / M, and accumulation of p21 protein. Simvastatin is 
able to remove resistance to apoptosis that occurs during treatment with bortezomib, by 
reducing geranylgeranyl pyrophosphate synthesis and cell survival mechanism dependant 
on this. (Fuchs et al., 2008) In IgM secreting cell lines and cells from Waldenstrom 
macroglobulinaemia, simvastatin showed antiproliferative and cytotoxic effects and 
stimulated the apoptosis. Simvastatin had a synergistic effect with bortezomib, 
dexamethasone and fludarabine by augmenting their cytotoxicity. (Moreau et al., 2008). 
A group of 23 patients with lymphoproliferative diseases, for which statins had not been 
contraindicated, was treated for 3 days with simvastatin at a dose of 120 mg/day. Serum 
CH level and that of total lipids decreased significantly (p<0.001 and, respectively,  
p = 0.016). Serum ALT decreased unsignificantly, while that of AST increased, the growth 
was close to the statistical significance limit, but was not higher than the upper normal level. 
Flowcytometric dosage of annexine V showed that simvastatin induced early and late 
apoptosis increase (p = 0.007, respectively, p = 0.003). By its effect on apoptosis, simvastatin 
could be an adjuvant treatment for patients with lymphoproliferative disorders. (Mihăilă et 
al., 2009) 
By their CH-lowering effect, statins are promising drugs for the treatment of lymphomas (63 
Winiarska et al., 2008). A female patient suffering from NHL with large B-cells whose 
primary location was the mammary gland had hypercholesterolemia, hypertriglyceridemia 
and was hypertensive. During the treatment with R-CHOP and radiotherapy that followed 
(30 Gy), she received lovastatin (20 mg/day) and verapamil. After the first 30 days of 
treatment, both CH and TG were normalized, and after the whole treatment, the patient has 
been in complete remission that persists today. (Mihăilă et al, 2008) Lovastatin was 
administered to the patient not only because she was dyslipidemic, but also because the 
literature claims that the drug is useful in malignant lymphomas, leukemias and multiple 
myeloma by its pleiotropic effects. In 1998 the first article about a farnesyltransferase 
inhibitor (L-744, 832) was published, inhibitor that proved to be effective in mice with 
mammary carcinomas and lymphomas (Mangues et al., 1998). Lovastatin acts by inhibition 
of geranylgeranylation, followed by reduction of intracellular signaling mechanisms, which 
results in reduction of time and dose-dependency of the viability of lymphoma cells in vitro. 
This is the result of apoptosis stimulation as well as of the decrease of lymphoma cells 
proliferation, the latter by induction of G1 arrest in cell cycle (van de Donk et al., 2003). 
In a rat lymphoma model lovastatin administration during radiotherapy led to cell cycle 
arrest in different phases, which justified the continuation of the treatment with this drug in 
the female patient during radiotherapy; the experimental model mentioned, the 
combination of lovastatin with radiotherapy resulted in a synergistic action (Rozados et al., 
2005, as cited in Mihăilă et al., 2008). Lovastatin administration did not preclude the 
response to polychemoterapy that included rituximab. In fact, although it is only one case, 
the experimental findings do not always overlap with clinical outcomes. The authors 
consider that the combination of lovastatin with verapamil favored the response to 
anticancer treatment and prevented the possible multidrug resistance (Mihăilă et al., 2008). 
The combination of lovastatin + R-CHOP did not lead to adverse effects. Six years after the 
end of therapy, the patient is still in complete remission. 
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In a cell line of acute promyelocytic leukemia (NB4) atorvastatin and fluvastatin showed to 
be potent stimulators of cell differentiation and apoptosis (Sassano et al., 2007). When to the 
treatment with idarubicin and high-dose cytarabine of patients with AML pravastatin was 
added, CR / CRp was observed in 11 of 15 new patients, out of which 8 of 10 had 
unfavorable cytogenetics, and 9 of 22 patients who received rescue medication that 
pravastatin did not influence the length of neutropenia, of thrombocytopenia or of the 
toxicity of chemotherapy. (Kornblau et al., 2007) 
Statins are active also in acute promyelocytic leukemia cells, where they augment the 
antileukemic response that depends on all-trans retinoic acid (ATRA). The c-Jun NH2-
terminal kinase pathway is required for leukemic cells differentiation induced by statins. 
Statins also intervene in modulating ATRA-dependent transcription. This was revealed by 
the selective expression of a large number of genes (400) when atorvastatin was 
administered together with ATRA. (Sassano et al., 2009) This drug combination could be a 
solution for reversing the ATRA-resistance of leukemic cells (Sassano et al., 2007). 
Unlike the subgroup of normal and AML cells CD34 (-), the CD34 (+) is more sensitive to 
lovastatin. Both populations of cells were strongly inhibited when lovastatin was added to 
chemotherapy. Leukemic cell samples from different patients with AML had heterogeneous 
sensitivity to lovastatin. Fifty percent of the patients with unfavorable treatment response 
had cytogenetic examination with poor prognosis and significantly more blasts in the 
peripheral blood. (de Jonge-Peeters et al., 2009) 
It was observed that high expression of CXCR4 correlates with a shorter survival time of 
patients with AML. In some models of cancer hypoxia it leads to the increase of CXCR4. On 
the other hand, increased pO(2) causes depletion of CH, which alters lipid rafts and leads to 
structural changes, which result in increased rejection of CXCR4 microparticles. (Fiegl et al., 
2009) Atorvastatin administred in doses of 16 mg/kg body wt showed to be effective in the 
inhibition of ascites tumor growth and induced apoptosis of a cell line of Daltons' 
Lymphoma Ascites that was transplanted into mice (Ajith et al., 2008). 
In vitro, simvastatin induced apoptosis of CLL cells, found in short term culture and 
contributed to lower BCL-2/BAX report; it was found that its effect of apoptosis induction is 
tumor-specific and does not affect normal lymphocytes. The association of simvastatin with 
fludarabine or cladribine synergistically induces DNA damages, and these lead to apoptosis. 
The proportion of cells found in apoptosis induced by simvastatin +/- chemotherapy was 
not correlated with the expression of negative prognostic markers of the disease (ZAP-70 
and CD38) or its stage in the RAI classification. (Podhorecka et al., 2010) 
The interaction of adhesion molecules, with fundamental role in cellular interaction 
processes, including those concerning EBV-transformed B cells is blocked by some statins. 
These drugs also inhibit intracellular activation of NF-kappaB and contribute to the 
emergence of transformed B-cell apoptosis. In mice with severe combined immune 
deficiency, simvastatin caused delayed emergence of the lymphomas induced by EBV. 
(Cohen et al., 2005) 
Both the simvastatin and the tipifarnib have cytotoxic effect on AML cell lines and their 
associated administration has a synergistic effect. This combination administered to 
CD34(+) AML cells resulted in the increase of the inhibitory effect only on normally 
responsive AML cells; however, the combination administred to CD34(-) AML cells had 
augmented inhibitory effect in all cells. (van der Weide et al., 2009) 
It was observed that statins are able to decrease the expression of BCL-2, an antiapoptotic 
molecule, favoring the appearance of apoptosis of CD4(+) CD28(null) T cells - a T aggressive 
www.intechopen.com
 
Dyslipidemia - From Prevention to Treatment 
 
400 
and long-lasting lymphocyte subpopulation, which can infiltrate the atheromatous plaques, 
contributing to the their destabilization, which facilitates the instalation of major coronary 
accidents. (Link et al., 2011) 
9. ABC transporters and cholesterol homeostasis 
In many neoplastic diseases, increased expression of proteins on which depends the 
multidrug resistance correlates with the presence of refractory disease. A small proportion 
of AML leukemia cells is responsible for the tumor proliferation and expansion. These are 
leukemic stem cells, primitive cells, which are frequently in a quiescent state. When they 
leave the quiescent state and progress along the cell cycle, these cells are characterized by 
the ability of self-renewal and express some ATP-binding cassette (ABC) transporters. It was 
observed that when some ABC transporters have a high expression in leukemia cells, the 
prognosis of patients with AML is reserved as the response to treatment is inadequate. (de 
Jonge-Peeters et al., 2007) 
The most studied transporter is the P-glycoprotein transporter (P-gp) - an ABC transporter 
responsible for unidirectional transmembrane translocation of the substrate (Gayet et al., 
2005). P-gp is frequently involved in the emergence of multidrug resistance during 
chemotherapy (Shu & Liu, 2007). The multidrug resistance gene encodes this membrane 
transporter. Not only P-gp occurs in CH homeostasis at the cellular level, but also the 
synthesis of CH and CH-esters affects ATP-ase (Bucher et al., 2007) and the transmembrane 
transport by P-gp (Bucher et al., 2007; Shu & Liu, 2007). The lipid structure of the cell 
membranes also depends on the P-gp function (Dos Santos et al., 2007).  
The ATP-ase activity of P-gp is controlled linearly by CH of the membrane structure. On the 
other hand, the decrease of membrane CH correlates with the non-linear decrease of the 
daunorubicin efflux induced by P-gp. An effective way to raise awareness of ALL CEM 
resistant to chemotherapy cells consists of partial depletion of the CH from cell membrane 
structure, that lowers the daunorubicin efflux by P-gp. (Gayet et al., 2005) 
CH is able to increase basal activity of P-gp ATP-ase and increase P-gp sensitivity to 
progesterone and verapamil, modulators of this transporter. (Bucher et al., 2007) LDL-
cholesterol can enlarge P-gp expression. In an experiment conducted in vitro, HMG-CoA 
reductase inhibitors were added to a primitive leukemia cells line (KG1a) and the 
observation was that lovastatin caused a decrease of 26% of P-gp expression, and 
pravastatin - a decrease of 16 %. (Connelly-Smith et al., 2007) But the CH derived from LDL 
was also able to restore sensitivity to chemotherapy of a human lymphoblastic leukemia 
cell line. It seems that the mechanism explaining this return is the restoration of the 
membrane CH and the reducing of the P-gp-associated ATPase to the same level. (Shu & 
Liu, 2007) The changes of the membrane CH quantity may be responsible for P-gp 
inhibition. It was observed that disassembly of lipid rafts can be produced both by the 
decrease of the CH content and by its increase. For a normal capacity of P-gp transport it 
is necessary to maintain accurate properties of membrane structures known as lipid raft. 
(Dos Santos et al., 2007) 
In a clinical trial involving patients with CLL the P-gp expression of lymphocytes from 
peripheral blood was determined flowcytometricaly. Those patients whose lymphocytes 
expressed P-gp were treated for 6 days with 80 mg lovastatin daily, then a new sample of 
peripheral blood was examined flowcytometricaly. Lymphocytes of six of the 27 studied 
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patients expressed P-gp; about 20% of them were positive. Following the administration of 
lovastatin only 7.33% of them also expressed P-gp (p = 0.016). Compared to the proportion 
of positive lymphocytes at baseline, the decline was of 63.35%. During the study, CH 
decreased statistically significantly, with 20.43%. There was no observation of the 
appearance of possible drug adverse effects. In conclusion, the 6 days therapy with 
lovastatin was able to reduce significantly the CH and the number of lymphocytes in the 
membranes where P-gp is expressed, so that this statin could contribute through its 
pleiotropic effects to reduce multidrug resistance, especially when it is followed by 
chemotherapy. (Mihăilă et al., 2010) 
This drug efflux pump can be inhibited by verapamil, too, the research made in vitro proved 
that it can reduce multidrug resistance. In such a study conducted in two patients with 
leukemic lymphoma resistant to treatment, verapamil was able to increase the intracellular 
amount of doxorubicin (Tidefelt et al., 1994). 
It was found that verapamil was able to overcome the P-gp - mediated resistance to 
doxorubicin and vincristine in a canine cell line of B cell lymphoma (GL-1) (Uozurmi et al., 
2005, as cited in Mihăilă et al., 2008). These experimental findings were not confirmed by 
parallel administration of chemosensitizer verapamil to chemotherapy (cyclophosphamide, 
doxorubicin, vincristine, and dexamethasone) in patients with medium and high level NHL 
found in advanced stages. This drug combination did not increase the therapeutic response 
and did not extend the survival in these patients as compared to those treated only with the 
mentioned chemotherapy (without verapamil) (Gaynor et al., 2001, as cited in Mihăilă et al., 
2008), but it cannot be excluded that it could be effective in some patients who develop 
multidrug resistance. But, in metastatic breast carcinoma that has become resistant to 
anthracyclines verapamil has showed that it is able to increase the survival of patients 
(Belpomme et al., 2000, as cited in Mihăilă et al., 2008). In the case of the patient described 
above with hypertension and primary mammary NHL, the evolution has been favorable 
under the combination of verapamil to chemo- and radiotherapy, that has resulted in a 
event-free survival of 6 years (up to the present day) (Mihăilă et al., 2008).  
In another study, 45 patients with proliferative haematological disorders were included in 
one of the following two groups: A - those who had hypertension and who received 
verapamil + chemotherapy, and B - those with normal blood pressure, who received only 
chemotherapy. Group A included 7 patients with chronic lymphoproliferations and 2 with 
chronic myleoproliferations; under treatment, both systolic and diastolic pressure decreased 
significantly in all patients in the group. Initially the serum CH level was higher than in the 
patients in group B (p = 0.004), while other biological tests did not vary significantly 
between group A and B. No adverse effects were observed during the study. The fact that 
the initial blood CH was higher in in patients in group A suggests that malignant cells of 
patients in group B captured more blood CH that contributed to their proliferation. 
Although the average survival was not significantly different between group A and B, in 
group A there were more patients with stable disease (77.78% versus 44.44% - p<0.0001) 
while in group B more patients had progressive disease (30.56 % versus 11.11% - p<0.0001). 
The deaths due to progressive disease were significantly more numerous in group B. The 
authors consider that verapamil is useful not only because of its antihypertensive effect, but 
also due to its pleiotropic effects through which it could influence the evolution of neoplasia 
by inhibiting P-gp function and the efflux of drugs from lymphoma or leukemia cells. 
(Mihăilă et al., 2008) 
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Various epidemiological studies have found that between blood lipids and various 
neoplastic diseases there are some correlations.  
Some authors found that in patients with newly diagnosed NHL the blood levels of CH, 
phospholipids and HDL-cholesterol had lower values than those of controls and the values 
of CH increased progressively after chemotherapy if the disease reached complete remission 
or was stationary, unlike those with disease progression, that their blood lipid levels were 
even lower. 
Nearly all the children with ALL when diagnosed and during chemotherapy revealed a 
predictable model of serum dyslipidemia that consisted of very low levels of HDL-
cholesterol, and elevated TG, and LDL-cholesterol, that regained normal values during the 
remission period. 
In children with ALL, treated with asparaginase, hypertriglyceridemia was frequently 
observed and it can be cause of acute pancreatitis and thrombosis. 
Imatinib mesylate, used for the treatment of patients with chronic myeloid leukemia, led to 
a diminishing of serum CH and TG values and CH depletion can inhibit cell proliferation. 
The young survivors of ALL, disease which they had in their childhood, especially those 
who received cranial radiotherapy, are likely to develop hyperlipidemia, insulin resistance, 
obesity, arterial hypertension and even MS soon after the treatment. 
Cranial irradiation favors more the appearance of MS by GH deficiency, lower level of 
insulin-like growth factor 1, fasting hyperinsulinemia, abdominal obesity and 
hyperlipidemia, especially in women. 
It is believed that CH is important for cell proliferation, because low serum CH values may 
be the result of high cellular CH need of cancerous cells. Low serum CH values correlate 
with elevated levels of CH in lymphocytes. Malignant, proliferative cells have an intense 
metabolism of CH, while decreased intake of CH is responsible for decreasing cell 
proliferation. 
An increase of lipoprotein lipase mRNA levels is present in CLL patients with shorter 
survival. 
CD5 antigen is responsible for CH synthesis and even for adipogenesis. It is known that 
malignant cells from CLL are undergoing a process of continuous stimulation due to CD5 
activation and cell survival. 
The loss of CH is responsible for the decrease in the number of sites that can fix some 
monoclonal antibodies, including CD20. Statins interfere with the detection of CD20 antigen 
as well as the antilymphomatous function of the rituximab, but this effect was not showed 
in some clinical studies. 
Statins reduce cellular proliferation and stimulate apoptosis of cancerous cells. By their 
pleiotropic effects, statins can be useful in the treatment of different diseases, like NHL, 
CLL, multiple myeloma and AML, as adjuvant therapy. 
The association of simvastatin with fludarabine or cladribine synergistically induces DNA 
damages, and these lead to apoptosis. 
Statins are active also in acute promyelocytic leukemia cells, where they augment the 
antileukemic response that depends on all-trans retinoic acid. 
The ATP-ase activity of P-gp, frequently involved in the emergence of multidrug resistance 
during chemotherapy, is controlled linearly by CH of the membrane structure. The changes 
of the membrane CH quantity may be responsible for P-gp inhibition. 
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This drug efflux pump can be inhibited by statins and verapamil. 
By their pleiotropic effects, statins are useful not only for dyslipidemia treatment, but also in 
antineoplastic therapy. 
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